Business Wire

International Energy Disputes Partner David Hesse Joins Hunton Andrews Kurth in London

22.8.2023 11:00:00 EEST | Business Wire | Press release

Share

David Hesse, an energy disputes attorney whose practice focuses on oil and gas litigation and arbitration matters with a strong emphasis on Africa has joined Hunton Andrews Kurth LLP as a partner in London.

Hesse advises states and national oil and gas companies on disputes, settlements, and upstream activities, as well as international tenders, refinery projects, farm-out agreements, and other contracts in the petroleum and petrochemical industries. His practice includes international commercial arbitration matters involving Anglophone and Francophone states and state entities in North, East, Central and West Africa.

Previously a partner with Clyde & Co., Hesse joins longtime colleague and collaborator Philip Mace as the newest additions to Hunton Andrews Kurth’s London-based energy team. Mace, who also recently joined the firm as a partner from Clyde & Co., is an experienced corporate lawyer whose practice is focused on energy and upstream oil and gas transactions.

“Robust global demand for large scale energy and infrastructure projects and the natural proliferation of disputes associated with those ventures continue to drive the need for a strong international arbitration and litigation practice,” said Tom Taylor, co-head of Hunton Andrews Kurth’s litigation team. “David is an outstanding lawyer whose experience and ability to navigate complex international disputes make him an ideal complement to the team.”

Hesse has extensive experience before international institutions including the International Chamber of Commerce (ICC) and International Centre for Settlement of Investment Disputes (ICSID). A selection of his notable representations prior to joining the firm include:

  • Advised the Government of Tanzania and the Tanzanian Electric Supply Company Limited (TANESCO) as co-lead international counsel with a local firm, in connection with related contract and treaty claims (ICSID) by Standard Chartered Bank.
  • Advised the Nigerian National Petroleum Corporation (NNPC) and supporting Nigerian counsel in connection with over $1 billion in claims by China National Offshore Oil Corporation (CNOOC) and South Atlantic Petroleum (SAPETRO) under a production sharing contract.
  • Advised the Government of Algeria and Sonatrach in connection with parallel proceedings (ICSID and UNCITRAL) by an oil and gas exploration company and an international shipping and logistics company for claims in excess of $8 billion relating to Algeria’s Windfall Profit Tax.
  • Advised the Government of Uganda and the Uganda Revenue Authority in connection with a $405 million claim by Heritage Oil (UNCITRAL) and a $473 million claim by Tullow Oil plc (ICSID) for recovery of capital gains tax under a production sharing agreement.
  • Advised ZCCM Investment Holdings PLC in connection with $2 billion in claims by Vedanta Resources Holdings Limited (UNCITRAL) relating to Konkola Copper Mines plc in Zambia.

“David’s practice complements our London-based projects and corporate offerings and reinforces our internationally recognized strength in the energy sector,” said Ferdinand Calice, managing partner of Hunton Andrews Kurth’s London office. “We are excited to welcome David to the firm.”

A recognized lawyer in Chambers Global and Legal 500, Hesse is also an Honorary Lecturer at the Centre for Energy, Petroleum and Mineral Law and Policy at the University of Dundee and a lecturer at the CWC School for Energy. He is a regular speaker at international arbitration and energy conferences, including Juris Conference, GAR Energy Disputes, and GAR Live.

Hesse received his undergraduate degree from the University of Cincinnati, his LLB (Maîtres) from the Universitie de Paris – La Sorbonne, and his LLM from Columbia Law School.

Hunton Andrews Kurth’s international arbitration and transnational litigation practice represents clients around the globe. We regularly handle investor-state arbitrations before the International Centre for Settlement of Investment Disputes (ICSID), and commercial arbitrations before the International Court of Arbitration of the International Chamber of Commerce (ICC); the London Court of International Arbitration (LCIA); the Singapore International Arbitration Centre (SIAC); the Permanent Court of Arbitration in The Hague; and the American Arbitration Association (AAA) and its international division, the International Centre for Dispute Resolution (ICDR). We also work with clients in multi-jurisdictional matters, working closely with counsel in local forums.

About Hunton Andrews Kurth LLP

With over 900 lawyers in the United States, Asia, Europe and the Middle East, Hunton Andrews Kurth LLP is a global firm that serves clients across a broad range of complex transactional, litigation and regulatory matters. The firm is known for its strength in the energy, financial services, real estate, and retail and consumer products industries, as well as its considerable experience in more than 100 distinct areas of practice, including privacy and cybersecurity, intellectual property, environmental, and mergers and acquisitions.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

The PR Office
hak@theproffice.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye